Micah J Hill1, Janelle C Cooper2, Gary Levy3, Connie Alford3, Kevin S Richter4, Alan H DeCherney3, Charles L Katz3, Eric D Levens4, Erin F Wolff3. 1. Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland. Electronic address: hillmicah@mail.nih.gov. 2. Washington Hospital Center, Washington, District of Columbia. 3. Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland. 4. Shady Grove Fertility Reproductive Science Center, Rockville, Maryland.
Abstract
OBJECTIVE: To assess ovarian reserve after methotrexate treatment for ectopic pregnancy or pregnancy of unknown location after assisted reproductive technology (ART). DESIGN: Retrospective cohort study. SETTING: Large ART practice. PATIENT(S): Women receiving methotrexate or surgery after ART. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Follicle-stimulating hormone (FSH), antral follicle count (AFC), and oocyte yield compared between women treated with methotrexate or surgery, with secondary outcomes of clinical pregnancy and live birth. RESULT(S): There were 153 patients in the methotrexate group and 36 patients in the surgery group. Neither group demonstrated differences in ovarian reserve or oocyte yield in a comparison of the before and after treatment values. The change in ovarian reserve and oocyte yield after treatment were similar between the two groups. The number of doses of methotrexate was not correlated with changes in ovarian reserve, indicating no dose-dependent effect. Time between treatment and repeat ART was not correlated with outcomes. Live birth in subsequent cycles was similar in the two groups. CONCLUSION(S): Ovarian reserve and subsequent ART cycle outcomes were reassuring after methotrexate or surgical management of ectopic pregnancy. No adverse impact of methotrexate was detected in this large fertility cohort as has been previously described elsewhere. Published by Elsevier Inc.
OBJECTIVE: To assess ovarian reserve after methotrexate treatment for ectopic pregnancy or pregnancy of unknown location after assisted reproductive technology (ART). DESIGN: Retrospective cohort study. SETTING: Large ART practice. PATIENT(S): Women receiving methotrexate or surgery after ART. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Follicle-stimulating hormone (FSH), antral follicle count (AFC), and oocyte yield compared between women treated with methotrexate or surgery, with secondary outcomes of clinical pregnancy and live birth. RESULT(S): There were 153 patients in the methotrexate group and 36 patients in the surgery group. Neither group demonstrated differences in ovarian reserve or oocyte yield in a comparison of the before and after treatment values. The change in ovarian reserve and oocyte yield after treatment were similar between the two groups. The number of doses of methotrexate was not correlated with changes in ovarian reserve, indicating no dose-dependent effect. Time between treatment and repeat ART was not correlated with outcomes. Live birth in subsequent cycles was similar in the two groups. CONCLUSION(S): Ovarian reserve and subsequent ART cycle outcomes were reassuring after methotrexate or surgical management of ectopic pregnancy. No adverse impact of methotrexate was detected in this large fertility cohort as has been previously described elsewhere. Published by Elsevier Inc.
Authors: D Meirow; J Dor; B Kaufman; A Shrim; J Rabinovici; E Schiff; H Raanani; J Levron; E Fridman Journal: Hum Reprod Date: 2007-02-26 Impact factor: 6.918
Authors: Kurt Barnhart; Amy C Hummel; Mary D Sammel; Seema Menon; John Jain; Nahida Chakhtoura Journal: Fertil Steril Date: 2006-11-13 Impact factor: 7.329
Authors: Bárbara Oriol; Ana Barrio; Alberto Pacheco; José Serna; José Luis Zuzuarregui; Juan A Garcia-Velasco Journal: Fertil Steril Date: 2007-12-11 Impact factor: 7.329
Authors: Christina E Boots; Micah J Hill; Eve C Feinberg; Ruth B Lathi; Susan A Fowler; Emily S Jungheim Journal: J Assist Reprod Genet Date: 2016-03-04 Impact factor: 3.412